Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

215
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

753
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
753
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

808
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
808
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

34
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
34
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

731
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
731

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

Canadian journal of physiology and pharmacology·2026
Same author

International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.

Pharmacological reviews·2026
Same author

Placental apelin expression is low in early-onset fetal growth restriction but there is no association between maternal circulating apelin and pregnancy outcome.

Placenta·2026
Same author

International Union of Basic and Clinical Pharmacology. CXXI. Apelin receptor pharmacology in the human cardiovascular system and emerging clinical applications.

Pharmacological reviews·2026
Same author

Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.

American heart journal·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets.

British journal of pharmacology·2025

Related Experiment Video

Updated: Aug 15, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.4K

From ABCD to E for endothelin in resistant hypertension.

George R Abraham1, Anthony P Davenport2

  • 1Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK; Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Cell
|January 5, 2023
PubMed
Summary

Endothelin-1, a vasoconstrictor, regulates vascular tone. Endothelin receptor antagonists show promise for treating resistant hypertension, potentially marking a new clinical era.

More Related Videos

A Cell Culture Model of Resistance Arteries
10:54

A Cell Culture Model of Resistance Arteries

Published on: September 8, 2017

7.9K
Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.3K

Related Experiment Videos

Last Updated: Aug 15, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.4K
A Cell Culture Model of Resistance Arteries
10:54

A Cell Culture Model of Resistance Arteries

Published on: September 8, 2017

7.9K
Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

22.3K

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research

Background:

  • Endothelin-1 is a potent vasoconstrictor peptide regulating vascular tone.
  • Pharmacological blockade of the endothelin-1 pathway has limited established clinical applications.
  • Resistant hypertension remains a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of endothelin receptor antagonists in patients with resistant hypertension.
  • To explore the potential of targeting the endothelin-1 pathway for hypertension management.

Main Methods:

  • A recent clinical trial investigating endothelin receptor antagonists was analyzed.
  • The study focused on patients with treatment-resistant hypertension.

Main Results:

  • The clinical trial demonstrated a potential new role for endothelin receptor antagonists.
  • Findings suggest these antagonists may be effective in managing resistant hypertension.

Conclusions:

  • Endothelin receptor antagonists may transition into mainstream clinical practice for resistant hypertension.
  • Targeting the endothelin-1 pathway represents a promising therapeutic strategy.